Notably, SCORT‐CasRx‐pre‐gHoxB13 treatment significantly reduced the expression of extracellular vimentin and CD31, suggesting its inhibition of the angiogenesis associated with metastatic tumors. Here, VIM is linked to metastatic neoplasm.